Guardant Health (NASDAQ:GH) Director Sells $19,242.08 in Stock

Guardant Health, Inc. (NASDAQ:GH) Director Musa Tariq sold 116 shares of the stock in a transaction that occurred on Friday, October 16th. The shares were sold at an average price of $165.88, for a total transaction of $19,242.08. Following the transaction, the director directly owned 11,583 shares of the company’s stock, valued at $1,921,388.04. This represents a 0.99% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Musa Tariq also recently made the following trade(s):

• On Wednesday, September 16th, Musa Tariq sold 116 shares of Guardant Health stock. The stock was sold at an average price of $175.00, for a total transaction of $20,300.00.
• On Monday, August 17th, Musa Tariq sold 116 shares of Guardant Health stock. The stock was sold at an average price of $156.45, for a total transaction of $18,148.20.

Guardant Health Stock Down 0.5%

Guardant Health stock traded down $0.72 during trading on Monday, hitting $157.88. The stock had a trading volume of 1,869,720 shares, compared to its average volume of 2,211,743. The stock’s 50 day moving average is $167.94 and its two-hundred day moving average is $139.53. Guardant Health, Inc. has a 1 year low of $65.96 and a 1 year high of $191.05. The stock has a market cap of $21.19 billion, a price-to-earnings ratio of -45.24 and a beta of 1.58.

Guardant Health (NASDAQ:GH) last released its earnings results on Thursday, July 30th. The company reported ($0.42) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.76) by $0.34. The firm had revenue of $334.98 million during the quarter, compared to analysts’ expectations of $314.23 million. The business’s quarterly revenue was up 44.3% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.44) earnings per share. As a group, equities research analysts anticipate that Guardant Health, Inc. will post -3.02 EPS for the current fiscal year.

Institutional Investors Weigh In On Guardant Health

Institutional investors and hedge funds have recently modified their holdings of the company. Ninepoint Partners LP purchased a new position in Guardant Health during the second quarter valued at approximately $2,853,000. Orbimed Advisors LLC bought a new stake in Guardant Health during the 1st quarter worth approximately $40,199,000. GSA Capital Partners LLP purchased a new stake in Guardant Health in the 2nd quarter worth approximately $1,772,000. Eagle Health Investments LP purchased a new stake in Guardant Health in the 2nd quarter worth approximately $45,112,000. Finally, SWS Partners bought a new position in Guardant Health in the 2nd quarter valued at $11,190,000. 92.60% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on GH. Evercore reissued an “outperform” rating and issued a $200.00 price objective on shares of Guardant Health in a report on Monday, July 6th. JPMorgan Chase & Co. upped their price objective on shares of Guardant Health from $185.00 to $195.00 and gave the company an “overweight” rating in a report on Friday, July 31st. Morgan Stanley increased their target price on shares of Guardant Health from $185.00 to $200.00 and gave the stock an “overweight” rating in a research report on Monday, October 12th. Royal Bank Of Canada lifted their target price on shares of Guardant Health from $185.00 to $200.00 and gave the stock an “outperform” rating in a research note on Friday, July 31st. Finally, TD Cowen reissued a “buy” rating on shares of Guardant Health in a research report on Tuesday, August 25th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $190.00.

Guardant Health Company Profile

Guardant Health, Inc (NASDAQ:GH) is a precision oncology company that develops blood-based tests and data solutions designed to help detect cancer, guide treatment decisions and monitor patients over time. Its technologies analyze circulating tumor DNA and other molecular information from blood samples, supporting more accessible and less invasive alternatives to some tissue-based testing approaches.

The company’s products include Guardant360, which helps identify genomic alterations in advanced cancers and may inform targeted treatment selection; Guardant360 Response, designed to assess a patient’s response to therapy; and Guardant Reveal, which is used to detect minimal residual disease and recurrence risk in certain cancers.